Holen Sie sich die Stockscreener-App
2.24
1.82%
0.04
Vorhandelsmarkt:
2.23
-0.01
-0.45%
Schlusskurs vom Vortag:
$2.20
Offen:
$2.2
24-Stunden-Volumen:
98,791
Relative Volume:
0.06
Marktkapitalisierung:
$5.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.7442
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
+5.16%
1M Leistung:
+2.75%
6M Leistung:
-70.45%
1J Leistung:
-63.84%
1-Tages-Spanne:
$2.1766
$2.36
1-Wochen-Bereich:
$2.10
$2.36
52-Wochen-Spanne:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Vergleichen Sie ENSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.24 | 5.22M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Is Ensysce Biosciences Inc. stock poised for growthPredicted Market Direction Based on Momentum - Newser
How to manage a losing position in Ensysce Biosciences Inc.Asset Growth Pattern and Return Summary - Newser
Volatility clustering patterns for Ensysce Biosciences Inc.Risk-Managed Swing Setup and Signal Analysis - Newser
How strong is Ensysce Biosciences Inc. company’s balance sheetExceptional stock performance - jammulinksnews.com
What makes Ensysce Biosciences Inc. stock price move sharplyBreakout stock performance - jammulinksnews.com
How volatile is Ensysce Biosciences Inc. stock compared to the marketStay ahead with advanced stock screening tools - jammulinksnews.com
Why is Ensysce Biosciences Inc. stock attracting strong analyst attentionBuild a diversified portfolio for risk management - jammulinksnews.com
Has Ensysce Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewTop Performing Stocks - Newser
Why Ensysce Biosciences Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser
Is Ensysce Biosciences Inc. a good long term investmentHigh-yield investments - PrintWeekIndia
What drives Ensysce Biosciences Inc. stock priceExponential wealth increase - Autocar Professional
Published on: 2025-07-25 08:23:29 - PrintWeekIndia
Ensysce Biosciences Inc. Stock Analysis and ForecastRapid wealth multiplication - jammulinksnews.com
What analysts say about Ensysce Biosciences Inc. stockHigh-performance investment picks - jammulinksnews.com
When (ENSC) Moves Investors should Listen - news.stocktradersdaily.com
Ensysce Biosciences initiates Phase 3 study of PF614 - TipRanks
FDA-Reviewed Phase 3 Trial Begins: Revolutionary Opioid Promises Pain Relief Without Abuse Risk - Stock Titan
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614A Next-Generation OpioidDesigned to Deliver Powerful Pain Relief and Reduce Abuse - The Globe and Mail
How Ensysce Biosciences Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser
NAVY(boat pilot token) Tokenomics ExplainedHigh Return Potential - Newser
Where are the Opportunities in (ENSC) - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World
FDA-Designated Breakthrough Pain Drug Advances: New Solution to Opioid Overdose Crisis Shows Promise - Stock Titan
(ENSC) Investment Analysis - news.stocktradersdaily.com
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 71.5% - Defense World
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):